BET inhibitors as a therapeutic intervention in gastrointestinal gene signature-positive castration-resistant prostate cancer.
Shipra Shukla, Dan Li, Woo Hyun Cho, Dana M. Schoeps, Holly M. Nguyen, Jennifer L. Conner, Marjorie L. Roskes, Anisha B. Tehim, Gabriella Bayshtok, Mohini R. Pachai, Juan Yan, Nicholas A. Teri, Eric Campeau, Sarah Attwell, Patrick Trojer, , Yu Chen
This study identifies BET inhibitors as effective against GI transcriptome-positive CRPC by targeting HNF1A and HNF4G, improving outcomes in preclinical models.
Journal of Clinical Investigation · Jun 24, 2025Peer-reviewedCancer Biology